Means and methods for the specific inhibition of genes in cells and tissue of the cns and/or eye
CA 2482903 A1 · Owner: Acuity Pharmaceuticals, Inc. · Inventors: Goehring, Frank; Schulte, Ralf Wilhelm
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Described is a method for the specific modulation of the expression of target genes in cells and/or tissues of the CNS and/or eye wherein a composition , comprising one or more doubled stranded oligoribonucleotides (dsRNA) is introduced into the cell, tissue or organism outside the blood-brain or bloodretina barriers. Furthermore, a method for the identification and validation of the function of a gene is provided, wherein the method provides a test cell, test tissue or test organism, which allow information to be gained on the function of the target gene. In addition compositions and kits are , described useful for those methods. In particular components and methods for , the …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed April 16, 2003. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended April 16, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by April 16, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.